Rosetta Genomics (Rosetta Genomics) Change In Receivables : $0.00 Mil (TTM As of Jun. 2017)

View and export this data going back to 2007. Start your Free Trial

What is Rosetta Genomics Change In Receivables?

Rosetta Genomics's change in receivables for the quarter that ended in Jun. 2017 was $0.00 Mil. It means Rosetta Genomics's Accounts Receivable stayed the same from Dec. 2016 to Jun. 2017 .

Rosetta Genomics's change in receivables for the fiscal year that ended in Dec. 2016 was $2.60 Mil. It means Rosetta Genomics's Accounts Receivable declined by $2.60 Mil from Dec. 2015 to Dec. 2016 .

Rosetta Genomics's Accounts Receivable for the quarter that ended in Jun. 2017 was $0.47 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Rosetta Genomics's Days Sales Outstanding for the three months ended in Jun. 2017 was 49.51.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Rosetta Genomics's liquidation value for the three months ended in Jun. 2017 was $-3.43 Mil.

Rosetta Genomics Change In Receivables Historical Data

The historical data trend for Rosetta Genomics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rosetta Genomics Change In Receivables Chart

Rosetta Genomics Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Change In Receivables

Get a 7-Day Free Trial

-0.35

0.12

-0.28

-2.96

2.60

Rosetta Genomics Quarterly Data
	Dec10	Mar11	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Jun17
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Rosetta Genomics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Rosetta Genomics (OTCPK:ROSGQ) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Rosetta Genomics's Days Sales Outstanding for the quarter that ended in Jun. 2017 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.472	/	0.87	*	91
=	49.51

2. In Ben Graham's calculation of liquidation value, Rosetta Genomics's accounts receivable are only considered to be worth 75% of book value:

Rosetta Genomics's liquidation value for the quarter that ended in Jun. 2017 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1.325	-	5.108	+	0.75 * 0.472	+	0.5 * 0
=	-3.43

Rosetta Genomics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Rosetta Genomics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Rosetta Genomics (Rosetta Genomics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rosetta Genomics Ltd (OTCPK:ROSGQ) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 Plaut Street, Science Park, Rehovot, ISR, 76706

Website

http://www.rosettagenomics.com

Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.

Executives

Sabby Management, Llc	10 percent owner	115 HIDDEN HILLS DR, SPICEWOOD TX 78669
Sabby Healthcare Volatility Master Fund, Ltd.	10 percent owner	C/O SABBY MANAGEMENT, LLC, 10 MOUNTAINVIEW ROAD, SUITE 205, UPPER SADDLE RIVER NJ 07458

Rosetta Genomics (Rosetta Genomics) Headlines

From GuruFocus

Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS

By gurufocus • 12-09-2008